Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020



latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 1, 42, 40, 1, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 2, 1, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Agios Pharmaceuticals Inc, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..3), H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..4), H1 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H1 2020

List Of Figures


Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020 latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides an overview of the Hodgkin

USD 2000 View Report

B-cell Non-Hodgkins LymphomaMarket Insights, Epidemiology, and Market Forecast2028

B-cell Non-Hodgkins LymphomaMarket Insights, Epidemiology, and Market Forecast2028 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-cell NHL in

USD 6250 View Report

Non-Hodgkin Lymphoma - Pipeline Review, H2 2019

Non-Hodgkin Lymphoma - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2019, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.Non-Hodgkin

USD 2500 View Report

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H2 2019, provides an overview of the Hodgkin Lymphoma (Oncology)

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available